Key result
This editorial introduces a special issue on cardio-oncology, highlighting the growing incidence and complexity of cardiovascular toxicities associated with modern anticancer therapies.
Answers are grounded in this paper and cite their sources.
This editorial introduces a special journal issue on cardio-oncology, highlighting the growing importance of managing cardiovascular toxicities associated with modern anticancer therapies.
The treatment efficacy of patients with cancer has significantly improved in the past several decades, leading to a substantial prolongation of life in patients with cancer. This accomplishment, however, has been achieved at the expense of significant short-term and long-term toxicities, including cardiovascular (CV) complications. Chemotherapy and radiation therapy have been used for the treatment of cancer for several decades, and these therapies are not specific, affecting noncancer tissues, and often causing side effects. The most notable cardiac complication of chemotherapy is cardiomyopathy.1 More recent anticancer approaches, introduced into clinical practice within the past 2 decades, are targeted therapies and immunotherapy, involving the use of the tyrosine kinase inhibitors, human epidermal growth factor receptor targeting monoclonal antibodies, immune check point inhibitors, and T-cell transfer therapy (ie, chimeric T-cell receptor and tumor-infiltrating lymphocyte therapies). These novel approaches have revolutionized the treatment of many forms of cancer, but at apparent odds to their expected targeted promise, their clinical use is also associated with CV and non-CV toxicities.2–4 The growing number of patients with serious cancer therapy-related CV complications and a better recognition of these complications led to the appearance of a novel subfield in medicine called cardio-oncology or onco-cardiology (initially in the late 1990s). Cardio-oncology is a rapidly evolving medical subspecialty, encompassing investigation, diagnosis, prevention, monitoring, and treatment of CV diseases caused, promoted, or aggravated by anticancer therapy. At the start, cardio-oncology largely dealt with anthracycline-induced and trastuzumab-induced cardiomyopathy (trastuzumab is a human epidermal growth factor receptor targeted monoclonal antibodies introduced in 1998). A wide clinical use of targeted and immune therapies in the past decade has sharply increased the range of cancer therapy-induced CV toxicities and the number of patients with cancer therapy–mediated cardiotoxicity.2,3 Nowadays, cardio-oncology deals with cancer therapy–related complications being not only cardiomyopathy but also acute myocarditis, pericarditis, arrhythmias, orthostatic intolerance syndromes, and cytokine release syndrome (Fig. 1).1–3,5–7FIGURE 1.: Interplay between cardiovascular diseases and cancer therapy.There has been a rapid increase in the amount of anticancer agents and their clinical indications in the past decade, and this trend is likely to continue. It is expected that the number of patients with cancer with drug-induced CV toxicities and the range of these toxicities will continue to rise.2,4 Apart from direct adverse effects of anticancer drugs on the CV system, there are many factors that can be involved in cancer therapy–related CV toxicities. Pre-existing CV diseases, often encountered in newly diagnosed patients with cancer, predispose for the CV complications induced by cancer drugs, and active cancer-associated factors (stress, systemic inflammation, etc.) may also contribute to the drug-induced CV toxicities. It seems that cancer environment itself may aggravate pre-existing CV diseases or even cause CV diseases de novo.1 The aging of the general population, increasing the chance of getting cancer, and extended life span of aged cancer survivors (largely because of modern cancer therapy), are themselves risk factors for CV diseases. Most cancer drug–induced CV toxicities appear during course of treatment. Yet, serious cardiac complications related to cancer therapy may occur or remain after months, years, or even decades after the end of the therapy (such as anthracycline-induced and radiation-induced cardiomyopathy).1,3 Whether there are long-term consequences of the CV toxicities caused by modern anticancer therapies remain poorly understood or unknown. Cancer therapy–related CV toxicities are often serious, requiring a modification or even cessation of the cancer therapy. Currently, the treatment of cancer therapy–related CV toxicity is largely based on pragmatic assumptions.2 Understanding cancer drug–induced CV toxicities is critical for the management of the patients. The current issue of the Journal of Cardiovascular Pharmacology presents up-to-date information on several aspects of cardio-oncology. Guha et al8 reviewed cardiometabolic consequences of anticancer therapy, an important emerging area in cardio-oncology. Cardiometabolic abnormalities, a major cause of morbidity and mortality in the general population, are likely to be significantly involved in a wide range of cancer drug–mediated CV toxicities. Two reviews deal with cancer therapy–induced cardiac arrhythmias, frequently encountered and with often serious complications. Essa et al9 summarized the information on the occurrence and management of atrial and ventricular arrhythmias induced by chemotherapy. Burashnikov10 describes the available information on cancer drug–induced atrial fibrillation and underlying cellular mechanisms of this adverse effect. Bannister et al11 reviewed cardiotoxicities caused by chemotherapeutic agents and their treatment, focusing on the left ventricular systolic dysfunction, the most commonly encountered cancer therapy–mediated cardiotoxicity. Artico et al12 summarized the available information on the detection of cancer therapy–induced or aggravated cardiac structural abnormalities by multiple imaging technologies. Timely detection of such abnormalities is critical for the management of the patients. Finally, Chuquin et al13 addressed an important but poorly understood issue of the management of hypertension in cancer survivors. Hypertension is highly prevalent in cancer survivors, as a pre-existing disease, induced or aggravated by cancer therapy, or appearing de novo independent of cancer-related factors. Detection and proper treatment of hypertension in patients with cancer are vital for their morbidity and mortality. We trust our readers will find this series on cardio-oncology both informative and enjoyable. The lessons learned to date from this discipline have already had an impact on both medical practice and basic science.
No takes yet. Share an insight, caveat, or question.
Burashnikov et al. (2022) conducted an editorial in Cancer therapy-related cardiovascular complications. Anticancer therapy was evaluated. This editorial introduces a special issue on cardio-oncology, highlighting the growing incidence and complexity of cardiovascular toxicities associated with modern anticancer therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: